Myopia

The randomized controlled trial included 196 schoolchildren in Hong Kong aged 4 to 12 years with myopia who completed the study.

Research suggests that one drop of atropine is all it takes for beneficial effects.

A global systemic review recently found that women had less access to glasses than men in low- to middle-income regions.

Myopia management is not one-size-fits-all, writes Magdalena Stec, OD, FAAO.

All 3 concentrations evaluated in the study were associated with reduced myopia progression.

The analysis included studies 31 studies identified through Web of Science, PubMed, CNKI, and Wanfang databases through October 2025.

Maria Liu, OD, PhD, MPH, MBA, FAAO, is taking the recent decision as an opportunity to reassess the role atropine plays in myopia control.

This study sheds light on use of the 0.05% atropine, which has been reported to be effective against myopia progression in some but not all studies.

For Langis Michaud, OD, MSc, FAAO, FSLS, FBCLA, FEAOO, low-atropine options are a must for eye care providers in the treatment of myopia.

The study was carried out between July 8 and August 1, 2024, and included 127 eyes from 68 children aged 8–14 years.

The findings were presented at the 51st Annual Meeting of AAPOS in Boston, Massachusetts.

Meta-analysis finds refraction change better than axial length thresholds for tracking childhood myopia, urging growth-curve AL monitoring to flag retinal risk.

In the urge to intervene early, optometrists are turning to low-dose atropine as a tool to combat myopia progression.

The study evaluated the company’s Defocus Incorporated Multiple Segments Triple Enhanced Design (DIMS TED) myopia control lenses in children aged 4–12 with progressive myopia.

The lens was developed in collaboration with Brien Holden Vision Institute (BHVI).

Evolutions in AI, myopia management, and individualized care are on ODs' minds for the new year.

Understanding the different expectations between patients with these conditions is key to choosing the appropriate refractive surgery.

The organization reaffirmed that it stands by myopia defined as a chronic, progression disease.

An effective but underused resource with positive benefits for patients with myopia.

The trial met its primary efficacy and key secondary end points.

The FDA acknowledged the primary efficacy end point was met but determined the data did not confirm the effectiveness of low-dose atropine in children, according to the company.

The researchers noted the importance of comprehensive eye examinations, including cycloplegic refraction for diagnosing and managing common pediatric ocular conditions, especially in children who fail vision screening.

The lens works to slow the progression of myopia in children aged 6 to 12 years at the initiation of treatment.

Study participants were followed annually from 2006 to 2018 with cycloplegic refractions and ocular biometry; the parents were followed with noncycloplegic refractions and ocular biometry.